Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
Duchenne muscular dystrophy (DMD) is an X-linked inherited disorder. Patients present with decreased bone mineral density (BMD) due to glucocorticoid therapy and progressive muscle weakness. Bone remodeling allows bone volume and structure to be maintained and controlled by local and systemic factor...
Wedi'i Gadw mewn:
Prif Awduron: | Salvador Atilano-Miguel (Awdur), Lourdes Barbosa-Cortés (Awdur), Rocío Ortiz-Muñiz (Awdur) |
---|---|
Fformat: | Llyfr |
Cyhoeddwyd: |
Permanyer,
2022-01-01T00:00:00Z.
|
Pynciau: | |
Mynediad Ar-lein: | Connect to this object online. |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Eitemau Tebyg
-
Glucocorticoids for Duchenne Muscular Dystrophy
gan: J Gordon Millichap
Cyhoeddwyd: (2013) -
A qualitative investigation of RANKL, RANK and OPG in a rat model of transient ankylosis
gan: Curl Linda, et al.
Cyhoeddwyd: (2014) -
Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway
gan: Zhao Y, et al.
Cyhoeddwyd: (2020) -
Association of Genetic Variants of RANK, RANKL, and OPG with Ankylosing Spondylitis Clinical Features in Taiwanese
gan: Chin-Man Wang, et al.
Cyhoeddwyd: (2019) -
Pangasius djambal gelatin increases osteoprotegerin, decreases RANK and RANKL after tooth extraction in vivo
gan: Fredy Mardiyantoro, et al.
Cyhoeddwyd: (2023)